Back to Search
CHRISTINA N BALLANTYNE
Addiction (Substance Use Disorder) Counselor
NPI: 1013499375Individual
Specialties, Licenses & Credentials
Case Manager/Care Coordinator
Case Manager/Care Coordinator
Code: 171M00000X
Addiction (Substance Use Disorder) CounselorPrimary
Counselor — Addiction (Substance Use Disorder)
Code: 101YA0400X
CDCA.168090(OH)
Clinical Trials (2)
2
Linked Trials
0
Recruiting
2
With Results
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.
NCT00988364COMPLETEDPHASE4STUDY_DIRECTOR
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
NCT00687076COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Research & Publications (14)
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).
PMID 24267254·Atherosclerosis·2013
4-observational
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients.
PMID 21227624·J Vasc Surg·2011
4-observational
Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management.
PMID 17345122·World J Surg·2007
6-review
Pro-apoptotic low-density lipoprotein subfractions in type II diabetes.
PMID 17030034·Atherosclerosis·2007
7-preclinical
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
PMID 14757686·Circulation·2004
8-other
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
PMID 15383192·Curr Med Res Opin·2004
3-trial
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
PMID 12719279·Circulation·2003
3-trial
LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
PMID 12637336·Arterioscler Thromb Vasc Biol·2003
8-other
Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins.
PMID 12689919·Arterioscler Thromb Vasc Biol·2003
7-preclinical
Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription.
PMID 12695302·Circulation·2003
7-preclinical
Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity.
PMID 11805008·Clin Chem·2002
8-other
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
PMID 11375333·Diabetes·2001
7-preclinical
Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells.
PMID 11031216·Arterioscler Thromb Vasc Biol·2000
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 213 E CHESTNUT ST
MOUNT VERNON, OH 43050 - Phone
- (740) 326-9255
Quick Facts
- NPI
- 1013499375
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Clinical Trials
- 2
- Publications
- 14
Are you this provider?
Claim Your Profile